收费全文 | 362篇 |
免费 | 14篇 |
国内免费 | 3篇 |
耳鼻咽喉 | 4篇 |
儿科学 | 13篇 |
妇产科学 | 41篇 |
基础医学 | 36篇 |
口腔科学 | 3篇 |
临床医学 | 39篇 |
内科学 | 59篇 |
皮肤病学 | 7篇 |
神经病学 | 20篇 |
特种医学 | 50篇 |
外科学 | 41篇 |
综合类 | 1篇 |
预防医学 | 11篇 |
药学 | 21篇 |
肿瘤学 | 33篇 |
2023年 | 2篇 |
2022年 | 4篇 |
2021年 | 11篇 |
2020年 | 2篇 |
2019年 | 16篇 |
2018年 | 8篇 |
2017年 | 9篇 |
2016年 | 10篇 |
2015年 | 6篇 |
2014年 | 9篇 |
2013年 | 26篇 |
2012年 | 14篇 |
2011年 | 21篇 |
2010年 | 9篇 |
2009年 | 16篇 |
2008年 | 19篇 |
2007年 | 17篇 |
2006年 | 34篇 |
2005年 | 39篇 |
2004年 | 32篇 |
2003年 | 16篇 |
2002年 | 12篇 |
2001年 | 2篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1998年 | 5篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 3篇 |
1994年 | 6篇 |
1993年 | 4篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1980年 | 1篇 |
1978年 | 1篇 |
1962年 | 1篇 |
Our aim was to investigate the disease-free survival in patients with tongue squamous cell carcinoma receiving metronomic neoadjuvant chemotherapy with 5-fluorouracil prodrugs (UFT or S-1) plus bleomycin compared with those who had up-front surgery retrospectively.
MethodsIn this retrospective study, 108 patients with stages I to II tongue squamous cell carcinoma who had undergone surgery were divided into the “surgery group” or “neoadjuvant chemotherapy group.”
ResultsA total of 41 patients received up-front surgery; 67 received metronomic neoadjuvant chemotherapy with UFT plus bleomycin (39) or S-1 plus bleomycin (28). The rate of disease-free survival was the primary outcome measure. Neoadjuvant 5-fluorouracil prodrugs did not correlate higher with improved disease-free survival than up-front surgery (72 and 54%, respectively; hazard ratio for recurrence or death, 0.54; 95% confidence interval [CI], 0.28 to 1.03; P = 0.06). Patients who received S-1 were more likely than those who received UFT to have pathological complete response (46% vs. 15%; P = 0.007). Neoadjuvant S-1 significantly improved disease-free survival as compared with up-front surgery (79% vs. 54%; hazard ratio, 0.41; 95% CI, 0.15 to 0.98; P = 0.04). However, neoadjuvant UFT did not improve disease-free survival as compared with up-front surgery (67% vs. 54%, respectively; hazard ratio, 0.66; 95% CI, 0.31 to 1.33; P = 0.24).
ConclusionsNeoadjuvant S-1 chemotherapy, as compared with up-front surgery, significantly improved disease-free survival among patients with tongue squamous cell carcinoma.
Clinical relevanceA choice of drugs before neoadjuvant metronomic chemotherapy is needed.
相似文献